Welcome to our dedicated page for Niagen Bioscience news (Ticker: NAGE), a resource for investors and traders seeking the latest updates and insights on Niagen Bioscience stock.
Niagen Bioscience, Inc. (NASDAQ: NAGE) is a bioscience company focused on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging, and its news flow reflects that specialization. Company announcements frequently highlight developments around its patented nicotinamide riboside ingredient Niagen®, the Tru Niagen® consumer supplement line, and the Niagen Plus™ intravenous and injectable platform.
Readers following NAGE news can expect updates on product launches and line extensions, such as Tru Niagen Beauty, which combines Niagen with clinically studied ingredients to support the appearance of hair, skin, and nails. News items also cover commercial partnerships and distribution milestones, including the expansion of pharmaceutical-grade Niagen Plus IV and injections into hundreds of clinics and wellness centers across the United States.
Because Niagen Bioscience emphasizes evidence-based positioning, a significant portion of its news relates to clinical and scientific progress. This includes publication of randomized controlled trials using Niagen in specific populations, summaries of peer-reviewed research on NAD+ biology, and the evolution of educational platforms like AboutNAD®, which curates NAD+ research for consumers, clinicians, and scientists.
Investors and observers will also find regular coverage of financial and corporate developments, such as quarterly earnings releases, changes to full-year outlook, share repurchase authorizations, and intellectual property transactions involving core nicotinamide riboside patents. For anyone tracking the NAD+ category, the NAGE news page offers an ongoing view into how Niagen Bioscience advances its science, expands its product ecosystem, and manages its capital and IP strategy. Bookmark this page to monitor new studies, product initiatives, and regulatory or market updates that the company discloses over time.
Niagen Bioscience (NASDAQ:NAGE) reported Q2 2026 net sales of $29.8 million (vs. $31.1 million in Q2 2025), including $24.2 million from Tru Niagen. Direct-to-consumer website sales grew 23% year-over-year. Gross margin was 64.8%, with net income of $1.0 million ($0.01 per basic and diluted share) and adjusted EBITDA of $3.0 million.
For the first half of 2026, operating cash flow totaled $1.6 million, and cash and equivalents were $66.7 million. The company repurchased $2.8 million of stock. It launched the Niagen Plus telehealth platform, obtained LegitScript certification for at-home injection kits, and introduced NB4168, an oral NR prodrug for Ataxia-Telangiectasia, which received FDA Rare Pediatric Disease and EMA Orphan designations. Evotec was engaged for preclinical and IND-enabling studies, expected to begin in Q3 2026. Niagen guided 2026 e-commerce growth of 10%–15% and signaled higher operating expenses for strategic investments.
Niagen Bioscience (NASDAQ: NAGE) has selected Evotec (NASDAQ: EVO; FSE: EVT) as contract research organization to advance preclinical development of NB4168, an oral small-molecule candidate for Ataxia Telangiectasia (A-T). Evotec will run pharmacokinetic, pharmacodynamic and bioanalytical studies at its Verona, Italy campus using its INDiGO platform.
According to Niagen Bioscience, nonclinical data show substantially higher blood exposure for NB4168 versus NR chloride. NB4168 has received U.S. FDA Rare Pediatric Disease Designation and EMA Orphan Medicinal Product Designation for A-T. The company is progressing IND-enabling work and plans to submit an IND to begin human clinical studies.
Niagen Bioscience (NASDAQ: NAGE) reported a newly published peer-reviewed analysis in Aging Cell of three prior human studies and in vitro work evaluating Niagen® nicotinamide riboside (NR) on skeletal muscle epigenetic aging. The pooled analysis used seven established epigenetic clocks, including the muscle-specific MEAT clock, to measure epigenetic age acceleration (EAA), a biomarker of biological aging.
According to Niagen Bioscience, five-month supplementation with 1,000 mg/day Niagen NR in a twin study was associated with roughly a 2.5-year reduction in muscle EAA by the MEAT clock, with statistically significant EAA reductions also seen in DunedinPACE and PCHannum. Overall, six of seven skeletal muscle clocks shifted toward lower EAA, while one (PCGrimAge) increased. Blood-based clocks showed three significant EAA reductions. In cultured human myotubes, Niagen NR increased NAD+ levels 1.52-fold versus control without significant epigenetic-age or mitochondrial DNA changes, suggesting whole‑body factors may mediate in vivo effects. The company highlights these data as evidence that Niagen NR may influence muscle aging biomarkers and supports further research alongside exercise interventions.
Niagen Bioscience (NASDAQ: NAGE) announced that CEO Rob Fried and CFO Ozan Pamir will participate in Canaccord Genuity’s 46th Annual Growth Conference in Boston from August 11–13, 2026. Fried will join a fireside chat on Tuesday, August 11, at 2:00 p.m. ET, accessible via webcast registration at Summitcast, with a replay available on the Niagen Bioscience investor relations website.
According to Niagen Bioscience, management will also hold one-on-one meetings with institutional investors. The company highlights its NAD+-boosting portfolio, including Tru Niagen and Niagen Plus, and ongoing research under NAD Pharmaceuticals on its NB4168 molecule.
Niagen Bioscience (NASDAQ: NAGE) will release its second quarter 2026 financial results after the market close on Tuesday, August 4, 2026, and will host a conference call and live webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss results and provide a business update.
Investors can access the webcast, earnings press release, and financial exhibits via the Investor Relations section of the company’s website. A toll-free dial-in number 1 (833) 461-5787 with Conference ID 879 107 368 is also provided for live participation.
Niagen Bioscience (NASDAQ: NAGE) has appointed Abhijit Kale, Ph.D., as Senior Director of Global External Research, effective July 20, 2026. He will lead the company’s Global Niagen Research Program, managing its worldwide network of academic and clinical collaborations and helping guide scientific strategy in NAD+ biology and healthy aging.
Dr. Kale previously served as Scientific Review Officer at Hevolution Foundation, contributing to a $1 billion longevity research portfolio and evaluating more than 600 proposals, and has held leadership roles at the Buck Institute for Research on Aging, Deciduous Therapeutics and LevitasBio. The Niagen Research Program currently supports more than 175 ongoing and developing studies and has contributed to over 45 peer-reviewed clinical publications on Niagen, over 90% of which are independent. Under his leadership, Niagen Bioscience plans to further expand external research into areas such as pharmaceutical-grade Niagen injections and infusions, topical applications, and new NAD+ precursors.
Niagen Bioscience (NASDAQ: NAGE) announced that the U.S. FDA has granted Rare Pediatric Disease (RPD) Designation and the European Medicines Agency has granted Orphan Medicinal Product Designation (OMPD) to its oral small molecule candidate NB4168 for treating Ataxia Telangiectasia (A-T), a serious rare pediatric disease with no approved treatments.
According to Niagen Bioscience, NB4168 is engineered to deliver substantially greater nicotinamide riboside exposure with a differentiated pharmacokinetic and safety profile and is designed to increase NAD+, which supports DNA repair and cellular energy pathways disrupted in A-T. NB4168 is the first investigational drug from subsidiary NAD Pharmaceuticals.
Niagen Bioscience (NASDAQ:NAGE) announced that CEO Rob Fried will join a virtual fireside chat hosted by KCSA Strategic Communications on July 15, 2026, at 8 a.m. PDT. He will discuss the recently launched pharmaceutical program, the Company’s role in NAD+ science, and provide business updates.
The webcast will include a live Q&A, with live access via registration and a replay available on the company’s investor relations website.
Niagen Bioscience (NASDAQ:NAGE) launched a pharmaceutical program via subsidiary NAD Pharmaceuticals to develop therapies for accelerated aging and rare genetic diseases. The first investigational candidate, NB4168, a proprietary NAD+ precursor derivative, will initially target Ataxia Telangiectasia (A-T), a rare pediatric ATM gene disorder with no FDA-approved therapies.
NB4168 is designed to provide higher oral bioavailability than nicotinamide riboside (NR). Nonclinical pharmacokinetic studies showed substantially higher blood exposure to the active moiety versus NR chloride, supporting continued development under Niagen Bioscience's extensive NAD+ patent portfolio.
Niagen Bioscience (NASDAQ:NAGE) announced that senior management will present at the 16th Annual East Coast IDEAS Investor Conference on June 11, 2026, at The Westin Times Square in New York.
CEO Rob Fried will present from 2:40–3:15 PM ET, with a livestream available via the conference host’s website. CFO Ozan Pamir will attend for one-on-one investor meetings.